Biogen
BIIB

$200.81

0.64%

Market Cap: $29.2B

About: Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.

Employees: 7,570

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,686 funds

0

Analysts bullish %

of 17 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

38% more funds holding in top 10

Funds holding in top 10: 8 [Q1] → 11 (+3) [Q2]

7% more capital invested

Capital invested by funds: $27.8B [Q1] → $29.7B (+$1.88B) [Q2]

0.72% less ownership

Funds ownership: 88.7% [Q1] → 87.98% (-0.72%) [Q2]

6% less repeat investments, than reductions

Existing positions increased: 311 | Existing positions reduced: 330

1% less funds holding

Funds holding: 925 [Q1] → 914 (-11) [Q2]

10% less first-time investments, than exits

New positions opened: 99 | Existing positions closed: 110

11% less call options, than puts

Call options by funds: $314M | Put options by funds: $353M

See Fund Rankings

Research analyst outlook

17 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$190

5%

downside

Avg. target

$276

37%

upside

High target

$317

58%

upside

17 analyst ratings

14 positive

82%

3 neutral

18%

0 negative

0%

Needham Ami Fadia 55% 1-year accuracy 70 / 128 met price target	42%upside $285	Buy Reiterated	4 Sept 2024
Needham Ami Fadia 55% 1-year accuracy 70 / 128 met price target	42%upside $285	Buy Reiterated	19 Aug 2024
Mizuho Salim Syed 44% 1-year accuracy 8 / 18 met price target	25%upside $251	Outperform Maintained	6 Aug 2024
Truist Securities Srikripa Devarakonda 67% 1-year accuracy 14 / 21 met price target	50%upside $302	Buy Reiterated	5 Aug 2024
Needham Ami Fadia 55% 1-year accuracy 70 / 128 met price target	42%upside $285	Buy Maintained	5 Aug 2024

See Analyst Rankings

Financial journalist opinion

Based on 10 articles about BIIB published over the past 30 days

Zacks Investment Research

Biogen's Phase II/III SMA Study for Higher Spinraza Dose Meets Goals

BIIB's pivotal mid to late-stage study evaluating a higher dosing regimen for Spinraza to treat SMA in infants meets the primary and secondary goals.

Biogen's Phase II/III SMA Study for Higher Spinraza Dose Meets Goals

Biogen Inc.'s (BIIB) Morgan Stanley's 22nd Annual Global Healthcare Conference Transcript

Biogen Inc. (NASDAQ:BIIB ) Morgan Stanley's 22nd Annual Global Healthcare Conference September 4, 2022 10:00 AM ET Company Participants Mike McDonnell – Chief Financial Officer Priya Singhal – Executive Vice President and Head-Development Conference Call Participants Terence Flynn – Morgan Stanley Terence Flynn Okay, great. I think we're going to get started, but thanks for joining us, everyone.

Biogen Inc.'s (BIIB) Morgan Stanley's 22nd Annual Global Healthcare Conference Transcript

Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA

CAMBRIDGE, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced positive, topline data from the pivotal cohort (Part B) of the Phase 2/3 DEVOTE study evaluating the safety and efficacy of a higher dose regimen of nusinersen in treatment-naïve, symptomatic infants with spinal muscular atrophy (SMA). The investigational higher dose regimen of nusinersen comprises a more rapid loading regimen, two 50 mg doses 14 days apart, and a higher maintenance regimen, 28 mg, every 4 months, compared to the approved nusinersen regimen (SPINRAZA). The study met its primary endpoint at six months, achieving a statistically significant improvement in motor function in infants who received the higher dose regimen as compared to a prespecified matched sham (untreated) control group from the ENDEAR study.

Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA

Zacks Investment Research

Biogen Stock Declines 20.9% Year to Date: Time to Sell?

BIIB's reasonable valuation, an improving pipeline and better sales prospects of new drugs are good enough reasons to stay invested for now.

Biogen Stock Declines 20.9% Year to Date: Time to Sell?

Zacks Investment Research

Why Biogen Inc. (BIIB) is a Top Value Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Why Biogen Inc. (BIIB) is a Top Value Stock for the Long-Term

UK patients unlikely to get access to Eisai-Biogen's Alzheimer's drug

Alzheimer's patients in Britain's state-run health service is unlikely to get access to Eisai and Biogen's new Leqembi drug, after it was approved by the country's regulator but deemed too expensive for wide use on Thursday.

UK patients unlikely to get access to Eisai-Biogen's Alzheimer's drug

Biogen: Q2 Earnings, Share Price May Have Bottomed Out As CEO Makes Mark

Biogen's Q2 earnings show flat revenue growth but a 31% increase in non-GAAP EPS. The focus is on Alzheimer's drug Leqembi as potential revenue driver, now it has secured full FDA approval and is generating positive longer-term clinical data. Biogen's pipeline includes potential revenue contributors in Alzheimer's, Parkinson's, and kidney disease therapies, pain therapeutics and MS.

Biogen: Q2 Earnings, Share Price May Have Bottomed Out As CEO Makes Mark

The Motley Fool

Prediction: The Next Big Biotech Stock Boom Will Be in Longevity Drugs

Treating aging and its consequences will be a colossal market. The first seeds of the coming boom have already been planted.

Prediction: The Next Big Biotech Stock Boom Will Be in Longevity Drugs

OpenFold AI Research Consortium Welcomes Six New Members: Astex, Biogen, Congruence, Polaris Quantum, Psivant, and SandboxAQ

DAVIS, Calif.--(BUSINESS WIRE)--The non-profit consortium is developing publicly accessible advanced AI-based drug discovery software tools.

OpenFold AI Research Consortium Welcomes Six New Members: Astex, Biogen, Congruence, Polaris Quantum, Psivant, and SandboxAQ

The Motley Fool

A Blood Test Could Detect Early Alzheimer's. That Could Make These 2 Stocks Red-Hot Buys.

A blood test that checks for an abnormal protein could detect 90% of Alzheimer's cases. Eli Lilly recently obtained approval for an early Alzheimer's treatment, Kisunla.

A Blood Test Could Detect Early Alzheimer's. That Could Make These 2 Stocks Red-Hot Buys.

See News Rankings